These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The effects of (-)N-(chloroethyl)-norapomorphine on [3H]-apomorphine binding to striatal dopamine receptors. Goosey MW; Doggett NS Biochem Pharmacol; 1982 Nov; 31(22):3693-4. PubMed ID: 7181954 [No Abstract] [Full Text] [Related]
8. Similarities between the binding of 3H-piflutixol and 3H-flupentixol to rat striatal dopamine receptors in vitro. Hyttel J Life Sci; 1981 Feb; 28(5):563-9. PubMed ID: 6111013 [No Abstract] [Full Text] [Related]
9. Changes in dopamine receptors in mouse striatum following morphine treatments. de la Baume S; Patey G; Marçais H; Protais P; Costentin J; Schwartz JC Life Sci; 1979 Jun; 24(25):2333-42. PubMed ID: 573360 [No Abstract] [Full Text] [Related]
10. Selective labelling of dopamine (D2) receptors in rat striatum by [3H]domperidone but not by [3H]spiperone. Lazareno S; Nahorski SR Eur J Pharmacol; 1982 Jul; 81(2):273-85. PubMed ID: 7117377 [TBL] [Abstract][Full Text] [Related]
11. Effects of GTP on 3H-domperidone binding and its displacement by dopamine in rat striatal homogenates. Lazareno S J Recept Res; 1983; 3(1-2):163-75. PubMed ID: 6854546 [TBL] [Abstract][Full Text] [Related]
12. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Laduron PM; Leysen JE Biochem Pharmacol; 1979 Jul; 28(14):2161-5. PubMed ID: 496998 [No Abstract] [Full Text] [Related]
13. Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone. Van Nueten JM; Ennis C; Helsen L; Laduron PM; Janssen PA Life Sci; 1978 Aug; 23(5):453-7. PubMed ID: 692268 [No Abstract] [Full Text] [Related]
14. Chronic domperidone fails to increase striatal spiperone binding sites despite hyperprolactinemia: comparison with chronic haloperidol. Morgan DG; Sinha YN; Finch CE Neuroendocrinology; 1984 May; 38(5):407-10. PubMed ID: 6728123 [TBL] [Abstract][Full Text] [Related]
15. Prolactin-releasing effect of a novel anti-dopaminergic drug, domperidone, in the rat. Cocchi D; Gil-Ad I; Parenti M; Stefanini E; Locatelli V; Müller EE Neuroendocrinology; 1980; 30(2):65-9. PubMed ID: 7354891 [No Abstract] [Full Text] [Related]
16. Differential inhibitory effects of ascorbic acid on the binding of dopamine agonists and antagonists to neostriatal membrane preparations: correlations with behavioral effects. Heikkila RE; Cabbat FS; Manzino L Res Commun Chem Pathol Pharmacol; 1981 Dec; 34(3):409-21. PubMed ID: 7323442 [TBL] [Abstract][Full Text] [Related]
17. Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Hamblin MW; Leff SE; Creese I Biochem Pharmacol; 1984 Mar; 33(6):877-87. PubMed ID: 6712712 [TBL] [Abstract][Full Text] [Related]
19. Interaction of the putative dopamine autoreceptor agonists 3-PPP and TL-99 with [3H]apomorphine binding sites in rat striatal membranes. Williams M; Totaro JA Eur J Pharmacol; 1982 Dec; 86(1):35-42. PubMed ID: 7160432 [TBL] [Abstract][Full Text] [Related]
20. The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes. Kilpatrick GJ; Jenner P; Marsden CD Eur J Pharmacol; 1984 Dec; 107(1):71-8. PubMed ID: 6084599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]